At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 37 enrolled
Drug / intervention
BI 836826drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia
In Brief
A Phase 1 clinical trial evaluating BI 836826 for Leukemia, Lymphocytic, Chronic, B-Cell. Completed, enrolled 37 participants across 10 sites in 3 countries.
Detailed Summary
Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphocytic, Chronic, B-Cell
CountriesBelgium, France, Germany
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionMay 2017
Study CompletionJul 2017
TodayJul 2026
First PostedFeb 16, 2011
Enrollment StartFeb 11, 2011
Primary CompletionMay 30, 2017
Study CompletionJul 10, 2017
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 15.4 years ago
Interventions
BI 836826drug
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.